Response of psoriasis to a lymphocyte-selective toxin (DAB₃₈₉IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1. Weinstein, G.D. & Krueger, J.G. An overview of psoriasis. in Therapy of Moderate-to-Severe Psoriasis (eds Weinstein, G. D. & Gottlieb, A.B.) 1−22 (National Psoriasis Foundation, Portland, Oregon 1993).
2. Vallat, V.P. et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy. J. exp. Med. 180, 283−296 (1994). | Article | PubMed  | ISI | ChemPort |
3. Bos, J.D. et al. Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch. dermatol. Res. 281, 24−30 (1989). | PubMed  | ISI | ChemPort |
4. Gottlieb, A.B. et al. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J. exp. Med. 164, 1013−1028 (1986). | Article | PubMed  | ISI | ChemPort |
5. Gottlieb, A.B., Chang, C.K., Posnett, D.N., Fanelli, B. & Tarn, J.P. Detection of transforming growth factor alpha in normal, malignant, and hyper-proliferative human keratinocytes. J. exp. Med. 167, 670−675 (1988). | Article | PubMed  | ISI | ChemPort |
6. Elder, J.T. et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 243, 811−814 (1989). | PubMed  | ISI | ChemPort |
7. Nickoloff, B.J. & Naidu, Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30, 535−546 (1994). | PubMed  | ISI | ChemPort |
8. Henseler, T. & Christophers, E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol. 13, 450−456 (1985) | PubMed  | ISI | ChemPort |
9. Baadsgaard, O., Fisher, G., Voorhees, J.J. & Cooper, K.D. The role of the immune system in the pathogenesis of psoriasis. J. invest. Dermatol. 95, 32S−34S (1990). | PubMed  | ChemPort |
10. Chang, J.C.C. et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V3 and/or V13.1 genes. Proc. natn. Acad. Sci. U.S.A. 91, 9282−9286 (1994). | ChemPort |
11. Gottlieb, A.B. & Krueger, J.G. Role of T-lymphocytes (in psoriasis pathogenesis). in Psoriasis (ed. Dubertret, L.) 63−71 (ISED Publishing Co, Brescia, Italy, 1994)
12. Prinz, J.C. et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur. J. Immun. 24, 593−598 (1994). | ISI | ChemPort |
13. Bata-Csorgo, Z., Hammerberg, C., Voorhees, J.J. & Cooper, K.D. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. J. clin. Invest. 95, 317−327 (1995). | PubMed  | ChemPort |
14. Krueger, J.G. & Gottlieb, A.B. Growth factors, cytokines and eicosanoids (in psoriasis pathogenesis). in Psoriasis (ed. Dubertret, L.) 18−28 (ISED Publishing Co., Brescia, Italy, 1994)
15. Baker, B.S. et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br. J. Dermatol. 116, 503−510 (1987). | PubMed  | ISI | ChemPort |
16. Rizova, H. et al. The effect of anti-CD4 monoclonal antibody treatment on immunological changes in psoriatic skin. J. dermatol. Sci. 7, 1−13 (1994). | PubMed  | ChemPort |
17. Ackerman, C. et al. Recalcitrant psoriasis and pyoderma gangrenosum treated with FK506. J. invest. Dermatol. 96, 536 (1991). | ISI |
18. Petzelbauer, P., Stingl, G., Wolff, K. & Volc-Platzer, B. Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J. invest. Dermatol. 96, 362−369 (1991). | PubMed  | ISI | ChemPort |
19. Gottlieb, A.B. et al. Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation. J. invest. Dermatol. 98, 302−309 (1992). | PubMed  | ISI | ChemPort |
20. Khandke, L. et al. Cyclosporine in psoriasis treatment: Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor-alpha/epidermal growth factor receptor pathways. Arch. Dermatol. 127, 1172−1179 (1991). | Article | PubMed  | ISI | ChemPort |
21. Williams, D.P. et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Engng 1, 493−498 (1987). | ChemPort |
22. Waters, C.A. et al. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immun. 20, 785−791 (1990). | ISI | ChemPort |
23. Waldman, T.A. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immun. Today 14, 264−270 (1993). | Article | PubMed  |
24. Shaw, J.P. et al. Cytotoxic properties of DAB₄₈₆EGF and DAB₃₈₉EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. biol. Chem. 266, 21118−21124 (1991). | PubMed  | ISI | ChemPort |
25. Mansbridge, J.N. & Knapp, A.M. Changes in keratinocyte maturation during wound healing. J. invest. Dermatol. 89, 253−263 (1987). | PubMed  | ISI | ChemPort |
26. Valdimarsson, H., Baker, B.S., Jonsdottir, I., Powles, A. & Fry, L. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immun. Today 16, 145−149 (1995). | Article | PubMed  | ISI | ChemPort |
27. Paukkonen, K., Naukkarinen, A. & Horsmanheimo, M. The development of manifest psoriatic lesions in linked with the invasion of CD8+ T cells and CD11c+ macrophages into the epidermis. Arch. Dermatol. Res. 284, 375−379 (1992). | PubMed  | ISI | ChemPort |
28. Onuma, A. Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J. Dermatol. 21, 223−232 (1994). | PubMed  | ChemPort |
29. Gottlieb, S.L. et al. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis. A clinical and pathologic study. J. Am. Acad. Dermatol. (in the press).
30. Hammer, R.E., Maika, S.D., Richardson, J.A., Tang, J.P. & Taurog, J.D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta2m: An animal model of HLA-B27-associated human disorders. Cell 63, 1099−1112 (1990). | Article | PubMed  | ISI | ChemPort |
31. Carnaud, C. & Bach, J-F. Cellular basis of T-cell autoreactivity in autoimmune diseases. Immun. Res. 12, 131−148 (1993). | ISI | ChemPort |
32. Bacha, P.L. et al. Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy. Int. J. Cancer 49, 96−101 (1991). | PubMed  | ISI | ChemPort |
33. Krane, J.F. et al. Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. J. invest. Dermatol. 96, 983−986 (1991). | PubMed  | ISI | ChemPort |
34. Tomfohrde, J. et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264, 1141−1145 (1994). | PubMed  | ISI | ChemPort |
35. LeMaistre, C.F. et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB₄₈₆IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79, 2547−2554 (1992). | PubMed  | ISI | ChemPort |
36. Fredriksson, T. & Pettersson, U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157, 238−244 (1978). | PubMed  | ISI | ChemPort |

	Top

	Top